Marked enhancement of clinical efficacy of platelet GP Db/DIa blockade with c7E3 Fab (abciximab) linked to reduction in bleeding complications: outcome in the EPILOG and EPIC trials - Lincoff, A M (Circulation, 1996)
(suppl)